CQS (US)’s Intellia Therapeutics NTLA Stock Holding History

CQS (US)’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-72,934	Closed	-$5.3M	–	105
2022 Q1	$5.3M	Buy	+72,934	New	+$6.18M	0.37%	74

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CQS (US)'s NTLA Position: Q2 2022 in Review

CQS (US) sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 72,934 shares — an estimated $5.3M sold.

CQS (US) first reported a position in NTLA in Q1 2022 and held it in 1 quarter. The position peaked at $5.3M in Q1 2022. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

CQS (US) reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
CQS (US) sold 72,934 Intellia Therapeutics shares in Q2 2022, an estimated $5.3M.
CQS (US) first reported a position in Intellia Therapeutics in Q1 2022 and held it in 1 quarter.
CQS (US)'s Intellia Therapeutics position peaked at $5.3M in Q1 2022.
299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on CQS (US)'s 13F filing for Q2 2022, filed 12 Aug 2022.